Review





Similar Products

90
Thermo Fisher sirna foxc1 (s223547)
Sirna Foxc1 (S223547), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/bca+protein+assay+kit/pm39892782-80-16-18
Average 90 stars, based on 1 article reviews
sirna foxc1 (s223547) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Ribobio co sirna targeting foxc1
Sirna Targeting Foxc1, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/foxc1+sirna/pm39753198-79-0-16
Average 90 stars, based on 1 article reviews
sirna targeting foxc1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sangon Biotech sirnas against linc01614 and foxc1
MiR-138-5p targets <t>FOXC1</t> to negatively regulate the expression of FOXC1. ( A ) Prediction of the potential target genes of miR-138-5p using the ENCORI, TargetScan, miRDB, and miRTarBase databases. ( B ) The effects of co-transfection with miR-138-5p mimics/NC and FOXC1-WT or FOXC1-MUT were examined using dual-luciferase reporter gene assays. ( C ) Effects of FOXC1 expression in OSCC cells transfected with miR-138-5p mimics or inhibitors. ( D – G ) Effects of co-transfection with the miR-138-5p inhibitor and control or si-FOXC1, on the growth, migration, invasion, and apoptosis of OSCC cells, as determined by colony formation, wound healing, and Transwell assays, and flow cytometric analyses. * p < 0.05, ** p < 0.01, and *** p < 0.001.
Sirnas Against Linc01614 And Foxc1, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/sirnas+against+linc01614+and+foxc1/pmc11593781-28-9-0
Average 90 stars, based on 1 article reviews
sirnas against linc01614 and foxc1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Ribobio co foxc1-sirna
MiR-138-5p targets <t>FOXC1</t> to negatively regulate the expression of FOXC1. ( A ) Prediction of the potential target genes of miR-138-5p using the ENCORI, TargetScan, miRDB, and miRTarBase databases. ( B ) The effects of co-transfection with miR-138-5p mimics/NC and FOXC1-WT or FOXC1-MUT were examined using dual-luciferase reporter gene assays. ( C ) Effects of FOXC1 expression in OSCC cells transfected with miR-138-5p mimics or inhibitors. ( D – G ) Effects of co-transfection with the miR-138-5p inhibitor and control or si-FOXC1, on the growth, migration, invasion, and apoptosis of OSCC cells, as determined by colony formation, wound healing, and Transwell assays, and flow cytometric analyses. * p < 0.05, ** p < 0.01, and *** p < 0.001.
Foxc1 Sirna, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/foxc1+sirna/pm39396563-116-7-8
Average 90 stars, based on 1 article reviews
foxc1-sirna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

92
OriGene sr320173cl
MiR-138-5p targets <t>FOXC1</t> to negatively regulate the expression of FOXC1. ( A ) Prediction of the potential target genes of miR-138-5p using the ENCORI, TargetScan, miRDB, and miRTarBase databases. ( B ) The effects of co-transfection with miR-138-5p mimics/NC and FOXC1-WT or FOXC1-MUT were examined using dual-luciferase reporter gene assays. ( C ) Effects of FOXC1 expression in OSCC cells transfected with miR-138-5p mimics or inhibitors. ( D – G ) Effects of co-transfection with the miR-138-5p inhibitor and control or si-FOXC1, on the growth, migration, invasion, and apoptosis of OSCC cells, as determined by colony formation, wound healing, and Transwell assays, and flow cytometric analyses. * p < 0.05, ** p < 0.01, and *** p < 0.001.
Sr320173cl, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/FOXC1+Human+siRNA+Oligo+Duplex/pmc11099035-428-22-20
Average 92 stars, based on 1 article reviews
sr320173cl - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

92
OriGene final sirna concentration
A , D Putative FOX-binding sites in regions of the human SLC3A2 or SLC7A5 locus as viewed on the UCSC genome browser ( http://genome.ucsc.edu ). Vertical lines on the ‘FOX sites’ and ‘FOXC sites’ track indicate putative FOX-binding sites predicted using HOMER (see Materials and Methods). Red boxes indicate evolutionarily conserved regions (ECRs) containing FOX-binding sites between human and mouse genomes that are conserved and aligned. B , E ChIP showing specific binding <t>of</t> <t>FOXC1</t> to the consensus FOX-binding sites within ECRs 1, 2, 3, 4, and 5 in SLC3A2 or ECRs 1, 2, and 3 in SLC7A5 in HRMVECs. C , F ChIP assays were performed using antibodies against FOXC1 and normal goat IgG. The binding of FOXC1 to candidate ECRs was determined with regular PCR and expressed as relative folds of input whose band intensity was normalized to 1. n = 8 biological duplicates from 4 independent experiments. Data are presented as mean ± SD. * p = 0.0142, ** p = 0.0026. Student’s two-tailed, unpaired t test ( C ). n = 5 from 3 independent experiments for ECR-1 and n = 8 from 4 independent experiments for ECR-2 and ECR-3. Data are presented as mean ± SD. ** p = 0.0057. Two-tailed, unpaired t test ( F ). RT-qPCR analysis of the <t>siRNA-mediated</t> knockdown of FOXC1 in HUVECs resulting in reduced mRNA expression levels of ( G ) FOXC1 ( H ) SLC3A2 and ( I ) SLC7A5 . n = 3 independent experiments. Data are presented as mean ± SD. *** p = 0.0004, **** p < 0.0001. Two-tailed unpaired t test is used for statistical analysis. Source data are provided as a file.
Final Sirna Concentration, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/FOXC1+Human+siRNA+Oligo+Duplex/pmc11099035-428-14-20
Average 92 stars, based on 1 article reviews
final sirna concentration - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
ABclonal Biotechnology 100pmol sirna foxc1
A , B Heatmap of differentially expressed genes of GSE26886 ( A ) and GSE53625 ( B ). C A Venn diagram illustrates the overlap of upregulated genes in both GSE26886 and GSE53625(fold change <t>>3.0).FOXC1</t> is upregulated in both GSE26886 and GSE53625. D TCGA database shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. E Esophageal squamous cell carcinoma tissue microarray from 79 patients shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. F The expression level of FOXC1 in ESCC was negatively correlated with patient survival rate. G , H The expression level of FOXC1 is corresponding to ESCC progression. I FOXC1 expression level in ESCC was higher than that in corresponding paraneoplastic tissues of 5 randomly selected patients. J FOXC1 is higher in ESCC cell lines especially in KYSE-150, ECA-109, TE-1, and KYSE-30 than in normal esophageal epithelial cell line HET-1A. * P < 0.05; ** P < 0.01; *** P < 0.001;**** p < 0.0001.
100pmol Sirna Foxc1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/FOXC1+Rabbit+pAb/pmc10899262-244-15-22
Average 93 stars, based on 1 article reviews
100pmol sirna foxc1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Thermo Fisher foxc1 sirna
A , B Heatmap of differentially expressed genes of GSE26886 ( A ) and GSE53625 ( B ). C A Venn diagram illustrates the overlap of upregulated genes in both GSE26886 and GSE53625(fold change <t>>3.0).FOXC1</t> is upregulated in both GSE26886 and GSE53625. D TCGA database shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. E Esophageal squamous cell carcinoma tissue microarray from 79 patients shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. F The expression level of FOXC1 in ESCC was negatively correlated with patient survival rate. G , H The expression level of FOXC1 is corresponding to ESCC progression. I FOXC1 expression level in ESCC was higher than that in corresponding paraneoplastic tissues of 5 randomly selected patients. J FOXC1 is higher in ESCC cell lines especially in KYSE-150, ECA-109, TE-1, and KYSE-30 than in normal esophageal epithelial cell line HET-1A. * P < 0.05; ** P < 0.01; *** P < 0.001;**** p < 0.0001.
Foxc1 Sirna, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/bca+protein+assay+kit/pm37391760-144-6-24
Average 90 stars, based on 1 article reviews
foxc1 sirna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology sirna against human foxc1
a Expression level of <t>FOXC1</t> mRNA by real-time RT-PCR analysis in ChiPSC12-CAT cells. Cells were cultured for 2, 4, 6, and 8 h after replacement with Day 1 differentiation medium containing only Tet-Express (Catalase [−]) or both Tet-Express and Shield-1 (Catalase [+]). Control: cells cultured without Tet-Express or Shield-1. Bars represent the means. N = 3. b Expression level of Oct3/4 mRNA by real-time RT-PCR analysis in ChiPSC12-CAT cells. N = 2. c Confirmation of FOXC1 knockdown in the early stage of differentiation on Day 1 by real-time RT-PCR analysis. Control: cells cultured without Tet-Express. Cells were treated FOXC1 siRNA on Day 0 and then cultured with differentiation medium containing Tet-Express. Bars represent the means. N = 3. Wilcoxon exact test (two-sided), * p = 0.0286. d FOXC1 knockdown in the early stage of differentiation rescued differentiation impairment on Day 7 in ChiPSC12-CAT cells producing ROS. Tet-Express: Cells were cultured with differentiation medium containing Tet-Express for 7 days. Tet-Express/ FOXC1 siRNA: cells were treated FOXC1 siRNA on Day 0 and then cultured with differentiation medium containing Tet-Express for 7 days. Scale bar, 20 μm. Results from one of three independent experiment are presented.
Sirna Against Human Foxc1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/FOXC1+siRNA/pmc08976013-222-0-8
Average 93 stars, based on 1 article reviews
sirna against human foxc1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Sangon Biotech foxc1 sirna
The mRNA expression level of CDC20 and <t>FOXC1</t> . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control
Foxc1 Sirna, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxc1+sirna/sirnas+against+linc01614+and+foxc1/pmc08094490-32-10-17
Average 90 stars, based on 1 article reviews
foxc1 sirna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


MiR-138-5p targets FOXC1 to negatively regulate the expression of FOXC1. ( A ) Prediction of the potential target genes of miR-138-5p using the ENCORI, TargetScan, miRDB, and miRTarBase databases. ( B ) The effects of co-transfection with miR-138-5p mimics/NC and FOXC1-WT or FOXC1-MUT were examined using dual-luciferase reporter gene assays. ( C ) Effects of FOXC1 expression in OSCC cells transfected with miR-138-5p mimics or inhibitors. ( D – G ) Effects of co-transfection with the miR-138-5p inhibitor and control or si-FOXC1, on the growth, migration, invasion, and apoptosis of OSCC cells, as determined by colony formation, wound healing, and Transwell assays, and flow cytometric analyses. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Genes

Article Title: LINC01614 Promotes Oral Squamous Cell Carcinoma by Regulating FOXC1

doi: 10.3390/genes15111461

Figure Lengend Snippet: MiR-138-5p targets FOXC1 to negatively regulate the expression of FOXC1. ( A ) Prediction of the potential target genes of miR-138-5p using the ENCORI, TargetScan, miRDB, and miRTarBase databases. ( B ) The effects of co-transfection with miR-138-5p mimics/NC and FOXC1-WT or FOXC1-MUT were examined using dual-luciferase reporter gene assays. ( C ) Effects of FOXC1 expression in OSCC cells transfected with miR-138-5p mimics or inhibitors. ( D – G ) Effects of co-transfection with the miR-138-5p inhibitor and control or si-FOXC1, on the growth, migration, invasion, and apoptosis of OSCC cells, as determined by colony formation, wound healing, and Transwell assays, and flow cytometric analyses. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: Sangon Biotech (Shanghai, China) provided siRNAs against LINC01614 and FOXC1, the pcDNA-LINC01614 overexpression plasmid, inhibitors and mimics for miR-138-5p, and negative controls (NCs).

Techniques: Expressing, Cotransfection, Luciferase, Transfection, Control, Migration

FOXC1 silencing counteracted the promoting effects of LINC01614 overexpression in OSCC cells. ( A , B ) Proliferative ability of OSCC cells (LINC01614, LINC01614+si-FOXC1, or NC) as determined by CCK-8 and colony formation assays. ( C ) Effects of co-transfection with LINC01614 and control or si-FOXC1 on the migratory potential of CAL-27 cells by wound healing assays. ( D ) Determination of the invasive potential of CAL-27 or SCC-9 cells transfected with LINC01614 or NC post-transfection with si-FOXC1 by Transwell assays. ( E ) Detection of the apoptosis of OSCC cells transfected with LINC01614 or LINC01614+si-FOXC1 and control OSCC cells by flow cytometry. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Genes

Article Title: LINC01614 Promotes Oral Squamous Cell Carcinoma by Regulating FOXC1

doi: 10.3390/genes15111461

Figure Lengend Snippet: FOXC1 silencing counteracted the promoting effects of LINC01614 overexpression in OSCC cells. ( A , B ) Proliferative ability of OSCC cells (LINC01614, LINC01614+si-FOXC1, or NC) as determined by CCK-8 and colony formation assays. ( C ) Effects of co-transfection with LINC01614 and control or si-FOXC1 on the migratory potential of CAL-27 cells by wound healing assays. ( D ) Determination of the invasive potential of CAL-27 or SCC-9 cells transfected with LINC01614 or NC post-transfection with si-FOXC1 by Transwell assays. ( E ) Detection of the apoptosis of OSCC cells transfected with LINC01614 or LINC01614+si-FOXC1 and control OSCC cells by flow cytometry. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: Sangon Biotech (Shanghai, China) provided siRNAs against LINC01614 and FOXC1, the pcDNA-LINC01614 overexpression plasmid, inhibitors and mimics for miR-138-5p, and negative controls (NCs).

Techniques: Over Expression, CCK-8 Assay, Cotransfection, Control, Transfection, Flow Cytometry

LINC01614 promoted the progression of OSCC in vivo. ( A ) Representative images of the subcutaneous OSCC tumors of nude mice. ( B , C ) Volumes and weights of the OSCC tumors. ( D ) Schematic depicting the role of the LINC01614/miR-138-5p/FOXC1 axis in the progression of OSCC. * p < 0.05.

Journal: Genes

Article Title: LINC01614 Promotes Oral Squamous Cell Carcinoma by Regulating FOXC1

doi: 10.3390/genes15111461

Figure Lengend Snippet: LINC01614 promoted the progression of OSCC in vivo. ( A ) Representative images of the subcutaneous OSCC tumors of nude mice. ( B , C ) Volumes and weights of the OSCC tumors. ( D ) Schematic depicting the role of the LINC01614/miR-138-5p/FOXC1 axis in the progression of OSCC. * p < 0.05.

Article Snippet: Sangon Biotech (Shanghai, China) provided siRNAs against LINC01614 and FOXC1, the pcDNA-LINC01614 overexpression plasmid, inhibitors and mimics for miR-138-5p, and negative controls (NCs).

Techniques: In Vivo

A , D Putative FOX-binding sites in regions of the human SLC3A2 or SLC7A5 locus as viewed on the UCSC genome browser ( http://genome.ucsc.edu ). Vertical lines on the ‘FOX sites’ and ‘FOXC sites’ track indicate putative FOX-binding sites predicted using HOMER (see Materials and Methods). Red boxes indicate evolutionarily conserved regions (ECRs) containing FOX-binding sites between human and mouse genomes that are conserved and aligned. B , E ChIP showing specific binding of FOXC1 to the consensus FOX-binding sites within ECRs 1, 2, 3, 4, and 5 in SLC3A2 or ECRs 1, 2, and 3 in SLC7A5 in HRMVECs. C , F ChIP assays were performed using antibodies against FOXC1 and normal goat IgG. The binding of FOXC1 to candidate ECRs was determined with regular PCR and expressed as relative folds of input whose band intensity was normalized to 1. n = 8 biological duplicates from 4 independent experiments. Data are presented as mean ± SD. * p = 0.0142, ** p = 0.0026. Student’s two-tailed, unpaired t test ( C ). n = 5 from 3 independent experiments for ECR-1 and n = 8 from 4 independent experiments for ECR-2 and ECR-3. Data are presented as mean ± SD. ** p = 0.0057. Two-tailed, unpaired t test ( F ). RT-qPCR analysis of the siRNA-mediated knockdown of FOXC1 in HUVECs resulting in reduced mRNA expression levels of ( G ) FOXC1 ( H ) SLC3A2 and ( I ) SLC7A5 . n = 3 independent experiments. Data are presented as mean ± SD. *** p = 0.0004, **** p < 0.0001. Two-tailed unpaired t test is used for statistical analysis. Source data are provided as a file.

Journal: Nature Communications

Article Title: FOXC1 regulates endothelial CD98 (LAT1/4F2hc) expression in retinal angiogenesis and blood-retina barrier formation

doi: 10.1038/s41467-024-48134-2

Figure Lengend Snippet: A , D Putative FOX-binding sites in regions of the human SLC3A2 or SLC7A5 locus as viewed on the UCSC genome browser ( http://genome.ucsc.edu ). Vertical lines on the ‘FOX sites’ and ‘FOXC sites’ track indicate putative FOX-binding sites predicted using HOMER (see Materials and Methods). Red boxes indicate evolutionarily conserved regions (ECRs) containing FOX-binding sites between human and mouse genomes that are conserved and aligned. B , E ChIP showing specific binding of FOXC1 to the consensus FOX-binding sites within ECRs 1, 2, 3, 4, and 5 in SLC3A2 or ECRs 1, 2, and 3 in SLC7A5 in HRMVECs. C , F ChIP assays were performed using antibodies against FOXC1 and normal goat IgG. The binding of FOXC1 to candidate ECRs was determined with regular PCR and expressed as relative folds of input whose band intensity was normalized to 1. n = 8 biological duplicates from 4 independent experiments. Data are presented as mean ± SD. * p = 0.0142, ** p = 0.0026. Student’s two-tailed, unpaired t test ( C ). n = 5 from 3 independent experiments for ECR-1 and n = 8 from 4 independent experiments for ECR-2 and ECR-3. Data are presented as mean ± SD. ** p = 0.0057. Two-tailed, unpaired t test ( F ). RT-qPCR analysis of the siRNA-mediated knockdown of FOXC1 in HUVECs resulting in reduced mRNA expression levels of ( G ) FOXC1 ( H ) SLC3A2 and ( I ) SLC7A5 . n = 3 independent experiments. Data are presented as mean ± SD. *** p = 0.0004, **** p < 0.0001. Two-tailed unpaired t test is used for statistical analysis. Source data are provided as a file.

Article Snippet: HUVECs were transfected for 48 h with control or FOXC1 targeting siRNA using a final siRNA concentration of 100 nM (Origene C, SR320173CL).

Techniques: Binding Assay, Two Tailed Test, Quantitative RT-PCR, Knockdown, Expressing

A , B Heatmap of differentially expressed genes of GSE26886 ( A ) and GSE53625 ( B ). C A Venn diagram illustrates the overlap of upregulated genes in both GSE26886 and GSE53625(fold change >3.0).FOXC1 is upregulated in both GSE26886 and GSE53625. D TCGA database shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. E Esophageal squamous cell carcinoma tissue microarray from 79 patients shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. F The expression level of FOXC1 in ESCC was negatively correlated with patient survival rate. G , H The expression level of FOXC1 is corresponding to ESCC progression. I FOXC1 expression level in ESCC was higher than that in corresponding paraneoplastic tissues of 5 randomly selected patients. J FOXC1 is higher in ESCC cell lines especially in KYSE-150, ECA-109, TE-1, and KYSE-30 than in normal esophageal epithelial cell line HET-1A. * P < 0.05; ** P < 0.01; *** P < 0.001;**** p < 0.0001.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: A , B Heatmap of differentially expressed genes of GSE26886 ( A ) and GSE53625 ( B ). C A Venn diagram illustrates the overlap of upregulated genes in both GSE26886 and GSE53625(fold change >3.0).FOXC1 is upregulated in both GSE26886 and GSE53625. D TCGA database shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. E Esophageal squamous cell carcinoma tissue microarray from 79 patients shows that FOXC1 is highly expressed in ESCC tissues compared to normal esophageal tissues. F The expression level of FOXC1 in ESCC was negatively correlated with patient survival rate. G , H The expression level of FOXC1 is corresponding to ESCC progression. I FOXC1 expression level in ESCC was higher than that in corresponding paraneoplastic tissues of 5 randomly selected patients. J FOXC1 is higher in ESCC cell lines especially in KYSE-150, ECA-109, TE-1, and KYSE-30 than in normal esophageal epithelial cell line HET-1A. * P < 0.05; ** P < 0.01; *** P < 0.001;**** p < 0.0001.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Microarray, Expressing

A , B Western blot analysis(A) and qPCR analysis(B) indicated that FOXC1 was significantly inhibited by siRNA in KYSE-150 and ECA-109 cells. (si-NC: si-Negative Control). C FOXC1 knockdown markedly inhibited the proliferation ability of ECA-109 and KYSE-150 cells indicated by CCK8 assay. D FOXC1 knockdown markedly inhibited the proliferation ability of ECA-109 and KYSE-150 cells indicated by colony formation assay. E FOXC1 knockdown markedly inhibited the invasion and migration ability of ECA-109 and KYSE-150 cells indicated by transwell assay. The scale bars represent 200μm. F FOXC1 knockdown markedly inhibited the sphere-formation ability of ECA-109 and KYSE-150 cells. The scale bars represent 200μm. G QPCR analysis indicated that FOXC1 knockdown markedly downregulated mRNA expression of cancer stem cell markers CD44 and CD133 in ECA-109 and KYSE-150 cells. H Western blot analysis indicated that FOXC1 knockdown markedly downregulated protein expression of cancer stem cell markers CD44 and CD133 in ECA-109 and KYSE-150 cells. I FACS indicated that FOXC1 knockdown markedly decreased the percentage of CD44+ cells. J , K Cell viability was detected after cells were treated with cisplatin at the indicated concentrations(1 μM) for 24 h by CCK8 assay ( J ) and apoptosis assay ( K ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.The p values were obtained by two-way ANOVA ( C , J ) or one-way ANOVA (others). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: A , B Western blot analysis(A) and qPCR analysis(B) indicated that FOXC1 was significantly inhibited by siRNA in KYSE-150 and ECA-109 cells. (si-NC: si-Negative Control). C FOXC1 knockdown markedly inhibited the proliferation ability of ECA-109 and KYSE-150 cells indicated by CCK8 assay. D FOXC1 knockdown markedly inhibited the proliferation ability of ECA-109 and KYSE-150 cells indicated by colony formation assay. E FOXC1 knockdown markedly inhibited the invasion and migration ability of ECA-109 and KYSE-150 cells indicated by transwell assay. The scale bars represent 200μm. F FOXC1 knockdown markedly inhibited the sphere-formation ability of ECA-109 and KYSE-150 cells. The scale bars represent 200μm. G QPCR analysis indicated that FOXC1 knockdown markedly downregulated mRNA expression of cancer stem cell markers CD44 and CD133 in ECA-109 and KYSE-150 cells. H Western blot analysis indicated that FOXC1 knockdown markedly downregulated protein expression of cancer stem cell markers CD44 and CD133 in ECA-109 and KYSE-150 cells. I FACS indicated that FOXC1 knockdown markedly decreased the percentage of CD44+ cells. J , K Cell viability was detected after cells were treated with cisplatin at the indicated concentrations(1 μM) for 24 h by CCK8 assay ( J ) and apoptosis assay ( K ). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.The p values were obtained by two-way ANOVA ( C , J ) or one-way ANOVA (others). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Western Blot, Negative Control, CCK-8 Assay, Colony Assay, Migration, Transwell Assay, Expressing, Apoptosis Assay

A The tumor incidence of different groups, including shFOXC1 or negative control group. ( n = 5/group). B FOXC1-knockout group had significantly lower tumor weight compared to the control group. C FOXC1-knockout group had significantly lower tumor volume compared to the control group. D–F Western blot analysis, qPCR analysis, and IHC indicated that FOXC1 was significantly inhibited by Lv-shFOXC1 in KYSE-150 cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.The p values were obtained by t test ( B , C , E ). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: A The tumor incidence of different groups, including shFOXC1 or negative control group. ( n = 5/group). B FOXC1-knockout group had significantly lower tumor weight compared to the control group. C FOXC1-knockout group had significantly lower tumor volume compared to the control group. D–F Western blot analysis, qPCR analysis, and IHC indicated that FOXC1 was significantly inhibited by Lv-shFOXC1 in KYSE-150 cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.The p values were obtained by t test ( B , C , E ). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Negative Control, Knock-Out, Western Blot

A Western blot analysis indicated that the knockdown of FOXC1 could downregulate CBX7 and IGF-1R expression in ECA-109 and KYSE-150 cells. B QPCR analysis indicated that the knockdown of FOXC1 could downregulate CBX7 and IGF-1R mRNA expression in ECA-109 and KYSE-150 cells. C ChIP assays revealed the direct binding of FOXC1 to the CBX7(right) or IGF-1R (left) promoter in KYSE-150 cells. D , E The mRNA expression of FOXC1, IGF-1R, and CBX7 was analyzed by qPCR(D), and The protein level of FOXC1, IGF-1R, and CBX7 was analyzed by western blot ( E ) after conducting transfection experiments using plasmids overexpressing CBX7 and IGF-1R in KYSE-150-shControl-LV, KYSE-150-shFOXC1-LV, ECA-109-shControl-LV, and ECA-109-shFOXC1-LV cell lines. F CCK8 assay indicated that the overexpression of CBX7 and IGF-1R significantly increased the proliferation ability of tumor cells, and rescued the negative impact of FOXC1 knockdown on tumor cell proliferation. G , H QPCR analysis ( G ) and western blot analysis ( H ) indicated that overexpressing CBX7 or IGF-1R could upregulate the expression of cancer stem cell marker CD44 and CD133 in ECA-109 and KYSE-150 cells and rescue the negative influence of FOXC1 knockdown. I-L.Upregulation of CBX7 and IGF-1R enhanced the resistance of KYSE-150 and ECA-109 cells to cisplatin through apoptosis assay ( I , J ) and CCK8 assay ( K , L ). M Upregulation of CBX7 and IGF-1R promoted the sphere-forming ability and rescued the influence of FOXC1 knockdown. The scale bars represent 200μm. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The p values were obtained by t test ( C ), two-way ANOVA ( F , K ), or one-way ANOVA (others). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: A Western blot analysis indicated that the knockdown of FOXC1 could downregulate CBX7 and IGF-1R expression in ECA-109 and KYSE-150 cells. B QPCR analysis indicated that the knockdown of FOXC1 could downregulate CBX7 and IGF-1R mRNA expression in ECA-109 and KYSE-150 cells. C ChIP assays revealed the direct binding of FOXC1 to the CBX7(right) or IGF-1R (left) promoter in KYSE-150 cells. D , E The mRNA expression of FOXC1, IGF-1R, and CBX7 was analyzed by qPCR(D), and The protein level of FOXC1, IGF-1R, and CBX7 was analyzed by western blot ( E ) after conducting transfection experiments using plasmids overexpressing CBX7 and IGF-1R in KYSE-150-shControl-LV, KYSE-150-shFOXC1-LV, ECA-109-shControl-LV, and ECA-109-shFOXC1-LV cell lines. F CCK8 assay indicated that the overexpression of CBX7 and IGF-1R significantly increased the proliferation ability of tumor cells, and rescued the negative impact of FOXC1 knockdown on tumor cell proliferation. G , H QPCR analysis ( G ) and western blot analysis ( H ) indicated that overexpressing CBX7 or IGF-1R could upregulate the expression of cancer stem cell marker CD44 and CD133 in ECA-109 and KYSE-150 cells and rescue the negative influence of FOXC1 knockdown. I-L.Upregulation of CBX7 and IGF-1R enhanced the resistance of KYSE-150 and ECA-109 cells to cisplatin through apoptosis assay ( I , J ) and CCK8 assay ( K , L ). M Upregulation of CBX7 and IGF-1R promoted the sphere-forming ability and rescued the influence of FOXC1 knockdown. The scale bars represent 200μm. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The p values were obtained by t test ( C ), two-way ANOVA ( F , K ), or one-way ANOVA (others). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Western Blot, Expressing, Binding Assay, Transfection, CCK-8 Assay, Over Expression, Marker, Apoptosis Assay

A , B KYSE-150 and ECA-109 cells were administrated with 10 ng/mL、50 ng/mL IGF-1 for 0, 4, 8, 12 h, and then the mRNA and protein levels of FOXC1 were examined by western blot analysis ( A ) and qPCR analysis ( B ). C , D KYSE-150 and ECA-109 cells were transfected with LV-shcontrol or LV-shFOXC1 lentiviral vectors and then treated with or without IGF-1 (50 ng/mL, 12 h). Next, the FOXC1 expression was analyzed by western blot analysis ( C ) and qPCR analysis ( D ). E CCK8 assay demonstrated that IGF-1 treatment increased the proliferation ability of KYSE-150 and ECA-109 cells, while FOXC1 knockdown reduced these capabilities. F , G Western blot analysis ( F ) and qPCR analysis ( G ) indicated that IGF-1 treatment increased the expression of cancer stem cell markers CD44 and CD133 while FOXC1 knockdown reduced the expression of CD44 and CD133. H , I IGF-1 treatment increased the tolerance to cisplatin while FOXC1 knockdown reduced the effect. The cell viability was detected by CCK8 assay ( H ) and apoptosis assay ( I ). J Sphere-formation assay indicated that IGF-1 treatment increased the sphere-formation ability of KYSE-150 and ECA-109 cells, while FOXC1 knockdown reduced these capabilities. The scale bars represent 200μm. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.The p values were obtained by two-way ANOVA ( E , H ) or one-way ANOVA (others). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: A , B KYSE-150 and ECA-109 cells were administrated with 10 ng/mL、50 ng/mL IGF-1 for 0, 4, 8, 12 h, and then the mRNA and protein levels of FOXC1 were examined by western blot analysis ( A ) and qPCR analysis ( B ). C , D KYSE-150 and ECA-109 cells were transfected with LV-shcontrol or LV-shFOXC1 lentiviral vectors and then treated with or without IGF-1 (50 ng/mL, 12 h). Next, the FOXC1 expression was analyzed by western blot analysis ( C ) and qPCR analysis ( D ). E CCK8 assay demonstrated that IGF-1 treatment increased the proliferation ability of KYSE-150 and ECA-109 cells, while FOXC1 knockdown reduced these capabilities. F , G Western blot analysis ( F ) and qPCR analysis ( G ) indicated that IGF-1 treatment increased the expression of cancer stem cell markers CD44 and CD133 while FOXC1 knockdown reduced the expression of CD44 and CD133. H , I IGF-1 treatment increased the tolerance to cisplatin while FOXC1 knockdown reduced the effect. The cell viability was detected by CCK8 assay ( H ) and apoptosis assay ( I ). J Sphere-formation assay indicated that IGF-1 treatment increased the sphere-formation ability of KYSE-150 and ECA-109 cells, while FOXC1 knockdown reduced these capabilities. The scale bars represent 200μm. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.The p values were obtained by two-way ANOVA ( E , H ) or one-way ANOVA (others). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Western Blot, Transfection, Expressing, CCK-8 Assay, Apoptosis Assay, Tube Formation Assay

A , B KYSE-150 cells were treated with IGF-1(50 ng/mL) for 12 h in the presence or absence of 10 μM、20 μM IGF-1R inhibitor Linsitinib, the protein expression of FOXC1, phosphorylated and total IGF-1R was detected by western blot analysis ( A ) and the mRNA expression of FOXC1 was detected by qPCR analysis ( B ). C-E.KYSE-150 cells were transiently transfected with control or p65 siRNA for 48 h and then treated with IGF-1(50 ng/mL) for 12 h. The protein level of p65, FOXC1 was detected by western blot analysis ( C ) and the mRNA of p65( D ),FOXC1 ( E ) was detected by qPCR analysis. F , G KYSE-150 cells were treated with IGF-1(50 ng/mL) for 12 h in the presence or absence of 10 μM、20 μM BAY11-7082, the protein expression of FOXC1, phosphorylated and total p65 was detected by western blot analysis ( F ) and the mRNA expression of FOXC1 was detected by qPCR analysis ( G ). H The ChIP assay showed the direct binding abilities of p65 to the FOXC1 promoter induced by IGF-1, and p65 inhibitor BAY11-7082 reduced the binding abilities of p65 to the FOXC1 promoter. I , J KYSE-150 cells were treated with IGF-1(50 ng/mL) for 12 h in the presence or absence of 10 μM GDC-0991,10 μM UO126, the protein expression of FOXC1,phosphorylated and total p65, phosphorylated and total Akt and ERK1/2 was detected by western blot analysis ( I ) and the mRNA expression of FOXC1 was detected by qPCR analysis ( J ). K The ChIP assay showed the direct binding abilities of p65 to the FOXC1 promoter induced by IGF-1, and PI3K inhibitor and ERK inhibitor reduced the binding abilities of p65 to the FOXC1 promoter. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The p values were obtained by one-way ANOVA ( B , D , E , G , H , J , K ,). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: A , B KYSE-150 cells were treated with IGF-1(50 ng/mL) for 12 h in the presence or absence of 10 μM、20 μM IGF-1R inhibitor Linsitinib, the protein expression of FOXC1, phosphorylated and total IGF-1R was detected by western blot analysis ( A ) and the mRNA expression of FOXC1 was detected by qPCR analysis ( B ). C-E.KYSE-150 cells were transiently transfected with control or p65 siRNA for 48 h and then treated with IGF-1(50 ng/mL) for 12 h. The protein level of p65, FOXC1 was detected by western blot analysis ( C ) and the mRNA of p65( D ),FOXC1 ( E ) was detected by qPCR analysis. F , G KYSE-150 cells were treated with IGF-1(50 ng/mL) for 12 h in the presence or absence of 10 μM、20 μM BAY11-7082, the protein expression of FOXC1, phosphorylated and total p65 was detected by western blot analysis ( F ) and the mRNA expression of FOXC1 was detected by qPCR analysis ( G ). H The ChIP assay showed the direct binding abilities of p65 to the FOXC1 promoter induced by IGF-1, and p65 inhibitor BAY11-7082 reduced the binding abilities of p65 to the FOXC1 promoter. I , J KYSE-150 cells were treated with IGF-1(50 ng/mL) for 12 h in the presence or absence of 10 μM GDC-0991,10 μM UO126, the protein expression of FOXC1,phosphorylated and total p65, phosphorylated and total Akt and ERK1/2 was detected by western blot analysis ( I ) and the mRNA expression of FOXC1 was detected by qPCR analysis ( J ). K The ChIP assay showed the direct binding abilities of p65 to the FOXC1 promoter induced by IGF-1, and PI3K inhibitor and ERK inhibitor reduced the binding abilities of p65 to the FOXC1 promoter. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The p values were obtained by one-way ANOVA ( B , D , E , G , H , J , K ,). Data are presented as mean ( n = 3) ± S.D. All experiments were performed at least three times.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Expressing, Western Blot, Transfection, Binding Assay

Sequences of each assay.

Journal: Cell Death Discovery

Article Title: IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma

doi: 10.1038/s41420-024-01864-0

Figure Lengend Snippet: Sequences of each assay.

Article Snippet: Cells were seeded into 6-well plates for transient knockdown transfection, followed by the transfection of 100pmol siRNA-FOXC1 (GenePharma, Shanghai, China) using HighGene (ABclonal, Wuhan, China) ECAh well, following the manufacturer’s guidance.

Techniques: Sequencing, Chromatin Immunoprecipitation

a Expression level of FOXC1 mRNA by real-time RT-PCR analysis in ChiPSC12-CAT cells. Cells were cultured for 2, 4, 6, and 8 h after replacement with Day 1 differentiation medium containing only Tet-Express (Catalase [−]) or both Tet-Express and Shield-1 (Catalase [+]). Control: cells cultured without Tet-Express or Shield-1. Bars represent the means. N = 3. b Expression level of Oct3/4 mRNA by real-time RT-PCR analysis in ChiPSC12-CAT cells. N = 2. c Confirmation of FOXC1 knockdown in the early stage of differentiation on Day 1 by real-time RT-PCR analysis. Control: cells cultured without Tet-Express. Cells were treated FOXC1 siRNA on Day 0 and then cultured with differentiation medium containing Tet-Express. Bars represent the means. N = 3. Wilcoxon exact test (two-sided), * p = 0.0286. d FOXC1 knockdown in the early stage of differentiation rescued differentiation impairment on Day 7 in ChiPSC12-CAT cells producing ROS. Tet-Express: Cells were cultured with differentiation medium containing Tet-Express for 7 days. Tet-Express/ FOXC1 siRNA: cells were treated FOXC1 siRNA on Day 0 and then cultured with differentiation medium containing Tet-Express for 7 days. Scale bar, 20 μm. Results from one of three independent experiment are presented.

Journal: Cell Death Discovery

Article Title: Endogenous ROS production in early differentiation state suppresses endoderm differentiation via transient FOXC1 expression

doi: 10.1038/s41420-022-00961-2

Figure Lengend Snippet: a Expression level of FOXC1 mRNA by real-time RT-PCR analysis in ChiPSC12-CAT cells. Cells were cultured for 2, 4, 6, and 8 h after replacement with Day 1 differentiation medium containing only Tet-Express (Catalase [−]) or both Tet-Express and Shield-1 (Catalase [+]). Control: cells cultured without Tet-Express or Shield-1. Bars represent the means. N = 3. b Expression level of Oct3/4 mRNA by real-time RT-PCR analysis in ChiPSC12-CAT cells. N = 2. c Confirmation of FOXC1 knockdown in the early stage of differentiation on Day 1 by real-time RT-PCR analysis. Control: cells cultured without Tet-Express. Cells were treated FOXC1 siRNA on Day 0 and then cultured with differentiation medium containing Tet-Express. Bars represent the means. N = 3. Wilcoxon exact test (two-sided), * p = 0.0286. d FOXC1 knockdown in the early stage of differentiation rescued differentiation impairment on Day 7 in ChiPSC12-CAT cells producing ROS. Tet-Express: Cells were cultured with differentiation medium containing Tet-Express for 7 days. Tet-Express/ FOXC1 siRNA: cells were treated FOXC1 siRNA on Day 0 and then cultured with differentiation medium containing Tet-Express for 7 days. Scale bar, 20 μm. Results from one of three independent experiment are presented.

Article Snippet: siRNA against human FOXC1 (SC-43766) was purchased from Santa Cruz Biotechnology Inc.

Techniques: Expressing, Quantitative RT-PCR, Cell Culture, Control, Knockdown

The mRNA expression level of CDC20 and FOXC1 . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control

Journal: BMC Medical Genomics

Article Title: Bioinformatic identification of hub genes and related transcription factors in low shear stress treated endothelial cells

doi: 10.1186/s12920-021-00971-6

Figure Lengend Snippet: The mRNA expression level of CDC20 and FOXC1 . a The mRNA expression level of FOXC1 . b The mRNA expression level of CDC20 . Sample size (n = 3). Data were expressed as mean ± SD. * indicates p value < 0.05 compared to control

Article Snippet: When the density reached 70–80%, ECs were transiently transfected with FOXC1 siRNA or scrambled control supplied by Sangon Biotech (Biotech (Shanghai) Co., Ltd. Shanghai, China) at the concentration of 100 nM to down-regulate the expression of FOXC1 .

Techniques: Expressing, Control